Immunovia announced the appointment of Karl Stone as Chief Operating Officer effective 1 March, 2023. As anticipated when the new management structure was announced in October 2022, Immunovia has now added a new Chief Operating Officer role to its executive team to align with strategic priorities and focus on the US commercialization of the IMMray(TM) PanCan-d test. The Chief Operating Officer will be responsible for leading R&D and Product Management to improve their productivity and efficiency.

Karl brings over 25 years of technical work experience from industrial bioprocessing through genomics, to IVD; he also has extensive experience in developing and commercializing IVD systems. Karl was one of the original members and the first Operations Director of Oxford Gene Technology, a pioneer of DNA microarray technology. During the pandemic Karl was Head of Operations at the Medicines Discovery Catapult, Lighthouse Lab - one of the UK´s network of COVID testing labs. He has also held leadership roles in operations, engineering and consulting across the life sciences industry.

Karl holds a Ph.D. in Biochemical Engineering from University College London, an M.Sc. in Medical Electronics and Physics from the University of London, and a B.Sc. in Electrical and Electronic Engineering from King's College London.